Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTamrin ChowdhuryCTC. Mircea S. TesileanuEKEmre Kocakavuk

Discussion

Loading...

Member takes

Overview

Whole-genome sequencing shows distinct genetic alterations in astrocytomas and oligodendrogliomas, indicating treatment responses differ.

Key Points

  • IDH-mutant gliomas include astrocytomas and oligodendrogliomas, diagnosed between ages 30-50.
  • Newly acquired point mutations in recurrent oligodendrogliomas were linked to higher mutation rates.
  • Multi-timepoint whole-genome sequencing of 206 patient samples revealed unique genetic alterations in response to therapy.
  • Distinct mutational signatures suggest divergent DNA damage responses in astrocytomas and oligodendrogliomas after treatment.

Cite This Study

Chowdhury et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccaa8https://doi.org/10.1101/2025.07.11.664189
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P05.24.B DISTINCT MOLECULAR PROFILES CHARACTERIZE THE NATURAL GROWTH RATES OF IDHMT CODELETED AND NON-CODELETED DIFFUSE LOW-GRADE GLIOMA WHO GRADE 2 (OLIGODENDROGLIOMA AND ASTROCYTOMA)2025
  2. 2P01.20.B CONVERGENT EVOLUTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS2025
  3. 3OS09.5.A RECURRENT COPY NUMBER ALTERATIONS DRIVE IDH-MUTANT ASTROCYTOMA DEVELOPMENT AND PROGRESSION2025
  4. 4EP12.16 NEXT-GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: A PATHWAY TO PRECISION THERAPEUTICS2025
  5. 5TET CpG sequence context specific DNA demethylation shapes progression of IDH-mutant gliomas2025